Creo Medical Group PLC (LSE:CREO) — Market Cap & Net Worth
Market Cap & Net Worth: Creo Medical Group PLC (CREO)
Creo Medical Group PLC (LSE:CREO) has a market capitalization of $633.60K (GBX5.21 Billion) as of May 4, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30448 globally and #870 in its home market, demonstrating a -1.75% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Creo Medical Group PLC's stock price GBX12.63 by its total outstanding shares 412473319 (412.47 Million). Analyse CREO cash flow conversion to see how efficiently the company converts income to cash.
Creo Medical Group PLC Market Cap History: 2016 to 2026
Creo Medical Group PLC's market capitalization history from 2016 to 2026. Data shows change from $4.09 Million to $633.60K (-17.84% CAGR).
Index Memberships
Creo Medical Group PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.08 Million | 0.07% | #198 of 722 |
Weight: Creo Medical Group PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Creo Medical Group PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Creo Medical Group PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.24x
Creo Medical Group PLC's market cap is 0.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.09 Million | $508.22K | -$1.61 Million | 8.05x | N/A |
| 2019 | $9.08 Million | $13.47K | -$15.91 Million | 674.21x | N/A |
| 2020 | $9.74 Million | $9.43 Million | -$20.32 Million | 1.03x | N/A |
| 2021 | $7.48 Million | $25.16 Million | -$24.59 Million | 0.30x | N/A |
| 2022 | $1.27 Million | $27.17 Million | -$26.94 Million | 0.05x | N/A |
| 2023 | $2.31 Million | $30.80 Million | -$21.70 Million | 0.07x | N/A |
| 2024 | $978.63K | $4.00 Million | -$28.70 Million | 0.24x | N/A |
Competitor Companies of CREO by Market Capitalization
Companies near Creo Medical Group PLC in the global market cap rankings as of May 4, 2026.
Key companies related to Creo Medical Group PLC by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Creo Medical Group PLC Historical Marketcap From 2016 to 2026
Between 2016 and today, Creo Medical Group PLC's market cap moved from $4.09 Million to $ 633.60K, with a yearly change of -17.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX633.60K | +27.53% |
| 2025 | GBX496.84K | -49.23% |
| 2024 | GBX978.63K | -57.61% |
| 2023 | GBX2.31 Million | +82.18% |
| 2022 | GBX1.27 Million | -83.05% |
| 2021 | GBX7.48 Million | -23.20% |
| 2020 | GBX9.74 Million | +7.18% |
| 2019 | GBX9.08 Million | -9.05% |
| 2018 | GBX9.99 Million | +186.33% |
| 2017 | GBX3.49 Million | -14.72% |
| 2016 | GBX4.09 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Creo Medical Group PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $633.60K USD |
| MoneyControl | $633.60K USD |
| MarketWatch | $633.60K USD |
| marketcap.company | $633.60K USD |
| Reuters | $633.60K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Creo Medical Group PLC
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices deli… Read more